IceCure Medical Ltd. (Nasdaq: ICCM) announced on March 2 2026 that an independent, investigator‑initiated study published in the peer‑reviewed journal PLOS One has demonstrated that its ProSense cryoablation system can reduce the volume of fibroadenomas by 92.9 % one year after treatment.
The study, conducted at the Premier Med Healthcare, Training, and Research Institute in Hungary and led by Dr. Teodora Filipov and Dr. Pál Ákos Deák, evaluated a cohort of patients with larger benign breast lesions and employed up to three cryoprobe relocations per procedure. Median volume reduction was 80.6 % at six months and 92.9 % at one year, confirming the safety and effectiveness of ProSense for non‑cancerous breast tumors.
By providing robust evidence for the use of liquid‑nitrogen–based cryoablation in larger fibroadenomas, the study may inform updates to treatment guidelines issued by professional societies such as the American Society of Breast Surgeons and could broaden the clinical indications and reimbursement pathways for ProSense in the United States and other markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.